AbbVie (NYSE:ABBV) Price Target Raised to $247.00 at BNP Paribas Exane

AbbVie (NYSE:ABBV) had its price objective lifted by investment analysts at BNP Paribas Exane from $218.00 to $247.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. BNP Paribas Exane’s target price would suggest a potential downside of 1.15% from the company’s current price.

A number of other analysts have also recently issued reports on the company. Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Piper Sandler restated an “overweight” rating and set a $298.00 target price on shares of AbbVie in a research report on Tuesday, June 23rd. UBS Group raised their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Guggenheim upped their target price on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $274.33.

AbbVie Stock Performance

ABBV stock traded up $1.90 during midday trading on Tuesday, reaching $249.87. 1,581,457 shares of the company were exchanged, compared to its average volume of 6,952,049. The company has a market cap of $441.47 billion, a price-to-earnings ratio of 70.43, a price-to-earnings-growth ratio of 0.82 and a beta of 0.30. AbbVie has a 1-year low of $190.75 and a 1-year high of $267.47. The stock’s 50-day simple moving average is $242.67 and its 200 day simple moving average is $225.28.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the firm posted $2.97 EPS. The company’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts anticipate that AbbVie will post 14.07 earnings per share for the current year.

Institutional Trading of AbbVie

A number of hedge funds have recently added to or reduced their stakes in ABBV. ACT Advisors LLC. increased its position in shares of AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares in the last quarter. Willner & Heller LLC lifted its holdings in shares of AbbVie by 0.7% during the 2nd quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock valued at $1,472,000 after acquiring an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC boosted its position in AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares during the period. Fielder Capital Group LLC increased its holdings in AbbVie by 1.7% in the 2nd quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after purchasing an additional 43 shares in the last quarter. Finally, Leslie Global Wealth LLC raised its position in AbbVie by 1.5% in the second quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock valued at $751,000 after purchasing an additional 44 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Apogee acquisition strengthens the pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, adding zumilokibart, an investigational treatment for atopic dermatitis with planned Phase 3 development. Positive Phase 2 results and potential applications in asthma and eosinophilic esophagitis could help expand AbbVie’s immunology portfolio beyond its existing growth drivers. The transaction is expected to close in the third quarter, subject to approvals. AbbVie to Acquire Apogee for $10.9 Billion
• Positive Sentiment: Botox may gain another indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence. If approved, the fifth use for the brand could broaden its addressable market and support continued growth in aesthetics. AbbVie’s Botox Just Got a Step Closer to a Fifth Use
• Positive Sentiment: Recent operating momentum supports the stock: AbbVie’s latest quarterly results exceeded revenue and earnings expectations, with revenue rising 10.2% year over year. Management cited strong performance from SKYRIZI, RINVOQ and neuroscience products, while brokerages continue to characterize the shares as a “Moderate Buy.” The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
• Neutral Sentiment: Analyst estimate trimmed but rating remains positive: Erste Group Bank lowered its FY2027 EPS forecast to $16.24 from $16.40, but retained a Buy rating. The modest reduction signals limited near-term concern rather than a broad change in the long-term outlook.
• Negative Sentiment: Debt-funded acquisition raises dividend-investor concerns: AbbVie is reportedly taking on approximately $8 billion of debt to help finance the Apogee deal. Although the acquisition could create future growth, added leverage may increase interest costs and constrain financial flexibility, particularly given AbbVie’s already substantial acquisition commitments. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.